About
Riboway Therapeutics is a Boston-based biotech leveraging AI to decode RNA biology and develop RNA-targeted therapeutics. We aim to revolutionize how targets are drugged and make every protein druggable. Our smart RNA-targeting technology enables precise control of protein expression and function—upregulating, downregulating, activating, or inhibiting proteins as needed.
Product
- Value proposition
- Specializes in controlling how proteins are made by targeting RNA with an AI-based platform to upregulate, downregulate, activate, or inhibit target proteins for therapeutic needs.
Founders
- Dr. Qinghong (Avery) Yan — Founder & CEO
- Dr. Sebastien Weyn — Co-founder and RNA computation lead
- Lijun Wu — Co-founder and advisor
Categories
Products
Key features
Technologies
Target conditions
Traction metrics
News
- Riboway Therapeutics - LinkedIn · 2025-06-01T00:00:00.000Z
- Riboway Therapeutics: Redefining the undruggable - Bio.News · 2025-09-05T00:00:00.000Z
- Resident Network | Biotech Startup Community at LabCentral · 2025-01-22T00:00:00.000Z
- Inside the AI BioHub: Meet the Inaugural Cohort - LabCentral · 2025-08-19T00:00:00.000Z
- The Innovation Space Kicks Off First Sector-Specific Science Inc ... · 2025-09-12T00:00:00.000Z
- WIB-Greater Boston: 10th Annual Lobster Pot Pitch Event · 2025-03-05T00:00:00.000Z
Browse similar startups
Related startups
- River Records — Boston, MA
- Rivvi AI, Inc — Cambridge, MA
- Senvera Therapeutics, Inc. A Curie.Bio Company — Boston, MA
- Shaws Pharmacy — Shrewsbury, MA
- Sidekick Bio — Boston, MA
- siRNAgen Therapeutics — Cambridge, MA
- Sarcomatrix — Reno, NV
- Stipple Bio — Cambridge, MA
- Symbiome — San Francisco, CA
- Synamics Therapeutics — Beverly Hills, CA
- TwoStep Therapeutics — San Carlos, CA
- Acrobat Genomics — San Carlos, CA
Profile updated Jul 29, 2026. Sources: riboway.com


